Article

Development and Consequences of Cannabis Dependence

Department of Psychiatry, University of Vermont, South Burlington 05403, USA.
The Journal of Clinical Pharmacology (Impact Factor: 2.48). 11/2002; 42(11 Suppl):28S-33S. DOI: 10.1002/j.1552-4604.2002.tb06000.x
Source: PubMed

ABSTRACT

The past 10 to 15 years of clinical and basic research have produced strong evidence demonstrating that cannabis can and does produce dependence. Clinical and epidemiological studies indicate that cannabis dependence is a relatively common phenomenon associated with significant psychosocial impairment. Basic research has identified a neurobiological system specific to the actions of cannabinoids. Human and nonhuman studies have demonstrated a valid withdrawal syndrome that is relatively common among heavy marijuana users. Last, clinical trials evaluating treatments for cannabis dependence suggest that this disorder, like other substance dependence disorders, is responsive to intervention, yet the majority of patients have difficulty achieving and maintaining abstinence. Of concern, treatment seeking for marijuana dependence has increased almost twofold over the past 10 years. This report briefly reviews selected research literature relevant to our current understanding of cannabis dependence, its associated consequences, and treatment efficacy.

Full-text

Available from: Brent A. Moore
BUDNEY AND MOOREDEVELOPMENT AND CONSEQUENCES OF CANNABIS DEPENDENCENOVEMBER SUPPLEMENT
Development and Consequences
of Cannabis Dependence
Alan J. Budney, PhD, and Brent A. Moore, PhD
T
he question of whether individuals become de-
pendent on marijuana has fueled much contro-
versy. For many years, the scientific community had
been reluctant to acknowledge the dependence poten-
tial of cannabis because certain types of experimental
findings were lacking. Until recently, attempts to dem-
onstrate that nonhuman animals would self-administer
cannabis (THC) in the laboratory were unsuccessful,
which contrasted with that observed with most other
drugs commonly abused by humans.
1,2
Second, early
studies of cannabis (THC) withdrawal failed to reveal a
syndrome that included reliable and substantial physi
-
cal symptoms such as those observed during classic
opioid, sedative, or alcohol withdrawal.
3
This lack of
evidence for physiological dependence, combined
with a poor understanding of the neurobiology of the
effects of cannabis, cast further uncertainty regarding
its dependence potential. Last, a paucity of clinical
data on cannabis dependence occasioned several com
-
mon beliefs that minimized its significance. Such be
-
liefs included the following: the prevalence of cannabis
dependence is very low, it exists only in the context of
polydrug dependence, it is not associated with sub
-
stantial functional impairment, and treatment is not
necessary because users can quit easily on their own.
4
In contrast, the past 10 to 15 years of clinical and ba-
sic research have produced strong evidence demon-
strating that cannabis can and does produce depend-
ence. Clinical and epidemiological studies indicate
that cannabis dependence is a relatively common phe-
nomenon associated with significant psychosocial
impairment. Basic research has identified a
neurobiological system specific to the actions of
cannabinoids. Human and nonhuman studies have
demonstrated a valid withdrawal syndrome that is rel
-
atively common among heavy marijuana users. Last,
clinical trials evaluating treatments for cannabis de
-
pendence suggest that this disorder , like other substance
dependence disorders, is responsive to intervention,
yet the majority of patients have difficulty achieving
and maintaining abstinence. Below, we briefly review
selected research literature relevant to our current un
-
derstanding of cannabis dependence and its associated
consequences.
RATES OF DEPENDENCE
AND ASSOCIATED PROBLEMS
The fourth edition of the Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV) and the ICD-10
Classification of Mental and Behavioural Disorders
consider cannabis dependence a reliable and valid psy
-
28S
J Clin Pharmacol 2002;42:28S-33S
From the Departments of Psychiatry and Psychology, University of Vermont.
Supported by NIDA grants DA12471, DA12157, and T32-DA07242. Ad
-
dress for reprints: Alan J. Budney, PhD, Associate Professor of Psychiatry
and Psychology, University of Vermont, Suite 12, 54 West Twin Oaks Ter
-
race, South Burlington, VT 05403.
DOI: 10.1177/0091270002238791
The past 10 to 15 years of clinical and basic research have
produced strong evidence demonstrating that cannabis can
and does produce dependence. Clinical and epidemiological
studies indicate that cannabis dependence is a relatively
common phenomenon associated with significant
psychosocial impairment. Basic research has identified a
neurobiological system specific to the actions of cannabinoids.
Human and nonhuman studies have demonstrated a valid
withdrawal syndrome that is relatively common among
heavy marijuana users. Last, clinical trials evaluating treat
-
ments for cannabis dependence suggest that this disorder,
like other substance dependence disorders, is responsive to
intervention, yet the majority of patients have difficulty
achieving and maintaining abstinence. Of concern, treat
-
ment seeking for marijuana dependence has increased al
-
most twofold over the past 10 years. This report briefly re
-
views selected research literature relevant to our current
understanding of cannabis dependence, its associated con
-
sequences, and treatment efficacy.
Journal of Clinical Pharmacology, 2002;42:28S-33S
Page 1
chiatric disorder , suggesting that individuals in the
general population experience cannabis dependence
in much the same way as they experience other sub
-
stance dependence disorders.
5,6
By definition, a diag
-
nosis of substance dependence indicates that an indi
-
vidual is experiencing a cluster of cognitive, behavioral,
or physiological symptoms associated with substance
use yet continues to use the substance regularly. Epide
-
miological studies indicate that the lifetime prevalence
of cannabis dependence approximates 4% of the U.S.
population, the highest of any illicit drug.
7,8
This high
rate of cannabis dependence is clearly affected by the
greater overall prevalence of marijuana use compared
to the use of other illicit drugs of abuse. Rates of condi
-
tional dependence—that is, the risk of developing de
-
pendence among those who have used the drug—pro
-
vide a better indicator of dependence potential. In this
regard, cannabis has a substantial, albeit lower, rate of
conditional dependence (9%) than substances such as
alcohol (15%), cocaine (17%), heroin (23%), or tobacco
(32%).
8
More frequent use results in greater risk of de
-
pendence. For example, rates of cannabis dependence
are estimated at 20% to 30% among those who have
used at least five times, and even higher estimates
(35%-40%) are reported among those who report near
daily use.
9,10
Those who develop cannabis dependence willingly
seek treatment for problems related to their use. For ex-
ample, Stephens and colleagues
11
reported that more
than 350 adults sought treatment during a 3-month pe-
riod in response to newspaper advertisements offering
assessment and treatment for persons concerned about
their marijuana use. The majority of those patients
were not currently abusing other substances, and most
reported multiple signs of dependence. Such treatment-
seeking patterns and profiles have been replicated in
other U.S. and Australian studies.
12,13
National trends
gleaned from the Treatment Episode Data Set
14
indicate
that the number of adults and adolescents who seek
and enroll in treatment for marijuana-related problems
is not small and has been increasing during the past de
-
cade. Indeed, the demand for treatment for marijuana-
related problems at state-approved substance abuse
programs doubled between 1992 and 1996 across the
United States, such that the percentage of illicit drug
abuse treatment admissions for marijuana (23%) ap
-
proximated that for cocaine (27%) and heroin (23%).
Similar increases in rates of treatment seeking for can
-
nabis problems during the 1990s have been reported in
Australia.
15
Interestingly, treatment admissions for in
-
dividuals younger than age 20 comprise about 45% of
all admissions.
14
Also, approximately 50% of indi
-
viduals seeking treatment for cannabis-related prob
-
lems have some involvement with the criminal justice
system.
The severity and specificity of the problems among
adults seeking treatment for marijuana-related prob
-
lems have been well documented. The great majority of
these patients have been using marijuana for more than
10 years, use marijuana on a daily basis, use multiple
times per day, and clearly meet DSM dependence crite
-
ria.
11-13
They exhibit substantial psychosocial impair
-
ment and psychiatric distress, report multiple adverse
consequences, report repeated unsuccessful attempts
to stop using, and perceive themselves as unable to
quit. The most common consequences mentioned are
procrastination, bad/guilty feelings, low productivity,
low self-confidence, interpersonal/family problems,
memory problems, and financial difficulties. A study
directly comparing marijuana- with cocaine-dependent
outpatients demonstrated that the two groups exhib
-
ited similar types of problems, but the marijuana abuser s
generally showed a less severe dependence syndrome.
12
Both groups met multiple DSM-III-R dependence crite-
ria, although the cocaine group reported a significantly
greater number of criteria (7.7 vs. 6.3). The groups did
not differ on the Medical, Legal, Family/Social, or Psy-
chiatric severity scales of the Addiction Severity Index,
but the cocaine group scored higher on the Employ-
ment severity scale. The cocaine group also scored
higher on the Drug and Alcohol severity scales, reflect-
ing greater polydrug abuse in the cocaine treatment
population. Both groups showed clinically significant
elevations on standardized psychiatric symptom
scales, but few between-groups differences were ob-
served. Sociodemographics such as marital status, in
-
come, and employment status also did not differ.
Although marijuana-dependent outpatients do not
typically experience the acute crises or dramatic conse
-
quences that many times drive alcohol-, cocaine-, or
heroin-dependent individuals into treatment, they
clearly show psychosocial impairment that warrants
clinical attention. In summary, evidence for a cannabis
dependence disorder is strong and indicative of a dis
-
order of substantial severity.
CANNABIS WITHDRAWAL
Evidence of a withdrawal syndrome has generally been
deemed a classic marker of the dependence potential of
a substance. In the 1970s, nonhuman studies of cessa
-
tion following chronic THC administration provided
evidence of a withdrawal response, but the effects were
not consistent and were deemed mild compared with
other substances such as opiates and sedatives.
3
Early
NOVEMBER SUPPLEMENT 29
S
DEVELOPMENT AND CONSEQUENCES OF CANNABIS DEPENDENCE
Page 2
studies with humans in residential laboratories also
found evidence of withdrawal.
3
Common symptoms
included decreased appetite, irritability, restlessness,
sleep difficulties, and uncooperativeness. These effects
were characterized as mild, transient, and without seri
-
ous medical complications and thus were considered
clinically insignificant when compared to the dramatic
medical and physiological symptoms associated with
severe opiate, sedative, or alcohol withdrawal. Hence,
investigation of cannabis withdrawal waned during
the 1980s.
The discovery of a cannabinoid receptor
16
and the
synthesis of a cannabinoid antagonist
17
renewed scien
-
tific interest in cannabis withdrawal. These advances
provided a better neurobiological understanding of the
drug’s mechanism of action and a means for conduct
-
ing antagonist challenge studies to test for cannabinoid
withdrawal. As reviewed elsewhere in this issue, such
studies have demonstrated a marked, precipitated
withdrawal syndrome in rats and dogs.
18,19
Recent stud-
ies on withdrawal in humans have also appeared in the
literature. Two placebo-controlled inpatient studies,
using moderate doses of oral THC and smoked mari-
juana, demonstrated withdrawal effects that included
anxiety, decreased contentment and food intake, de-
pressed mood, irritability, restlessness, sleep difficulty,
and stomach pain.
20,21
Controlled outpatient studies
have since provided data on the reliability, validity,
timecourse, and clinical significance of cannabis with-
drawal. One study examining 3-day abstinence periods
in heavy daily marijuana smokers validated specific ef-
fects of marijuana abstinence and showed they were re
-
liable and of clinically significant magnitude.
22
Spe-
cifically, decreased appetite, sleep difficulty, strange
dreams, aggression, anger, irritability, restlessness,
craving for marijuana, and weight loss were docu
-
mented during marijuana abstinence periods. A sec
-
ond outpatient study documented withdrawal during a
28-day period of abstinence in a similar population of
daily marijuana smokers.
23
Symptoms similar to those
reported in earlier studies remained elevated for at
least 7 to 14 days, as did Hamilton Depression and
Anxiety scale scores. Last, findings from a recent study
examining a 45-day marijuana abstinence period indi
-
cate that cannabis abstinence symptoms in heavy mari
-
juana users are of clinically significant magnitude and
follow a timecourse similar to that of other types of sub
-
stance withdrawal.
24
Clinical population studies of cannabis withdrawal
have been consistent with results observed in the labo
-
ratory, providing further support for a syndrome of
clinical significance. The majority of adolescents in
residential treatment and adults in outpatient treat
-
ment for cannabis dependence report histories of mari
-
juana withdrawal with symptom profiles similar to
those observed in the laboratory studies.
11,13,25,26
For ex
-
ample, we administered a 4-point (none, mild, moder
-
ate, and severe), 22-item Marijuana W ithdrawal Symp
-
tom Checklist to cannabis-dependent outpatients
enrolled in a treatment research clinic and found that
85% reported at least four abstinence symptoms.
25
The
most frequently reported symptoms were cravings
(95%), irritability (86%), nervousness (79%), de
-
pressed mood (74%), restlessness (74%), sleep diffi
-
culty (71%), and anger (71%). For many, these symp
-
toms were substantial, as 47% rated four or more
symptoms in the severe category. Thus, most cannabis-
dependent patients seeking treatment perceive and ex
-
pect that they will experience withdrawal symptoms
when they stop smoking.
Many of the symptoms of the cannabis withdrawal
syndrome overlap with those of other withdrawal syn-
dromes and perhaps most resemble those observed
with nicotine withdrawal.
27
Studies examining
neurochemical responses in animals following expo-
sure to and withdrawal from cannabinoids have ob-
served reductions in mesolimbic dopamine transmis-
sion and elevations in extracellular-releasing factor
concentrations in the limbic system that closely resem-
ble the responses seen with other major drugs of
abuse.
28,29
The behavioral consequences of these
neurobiological changes are consistent with the type of
negative affective symptoms reported by patients with-
drawing from cannabis and other substances and may
be primary contributing factors to the development and
maintenance of drug dependence. In summary, recent
research on cannabis withdrawal furthers the argu
-
ment that cannabis dependence is more similar to other
well-recognized types of substance dependence than
was previously believed.
TREATMENT STUDIES
The first randomized controlled trial evaluating treat
-
ment for adult cannabis dependence did not appear in
the literature until 1994.
30
Three additional random
-
ized trials have now been published.
31-33
Results across
studies indicate that the same types of psychosocial
treatments found effective for other substance depend
-
ence disorders are effective for cannabis dependence.
Coping-skills training, relapse prevention, and motiva
-
tional enhancement therapies have demonstrated effi
-
cacy compared to delayed treatment controls.
32,33
Con
-
tingency management interventions that provide
positive reinforcement contingent on abstinence from
cannabis, documented by urinalysis testing, can en
-
30S
J Clin Pharmacol 2002;42:28S-33S
BUDNEY AND MOORE
Page 3
hance treatment outcomes when integrated with other
effective therapies.
31
Similar types of interventions
have demonstrated efficacy in clinical trials for alco
-
hol, cocaine, and opiate dependence.
34-36
The aforementioned study comparing characteris
-
tics of marijuana- and cocaine-dependent outpatients
12
found that the marijuana patients were more ambiva
-
lent and less confident about stopping their marijuana
use than the cocaine group was about stopping use of
cocaine. These observations suggest that marijuana us
-
ers might have at least as much difficulty as cocaine pa
-
tients in initiating abstinence in treatment settings. In
-
deed, the magnitude of treatment response observed
across the marijuana trials appears similar to that
achieved with treatments for other substance de
-
pendence disorders. Only the minority (20%-40%)
of cannabis-dependent patients achieve abstinence
during treatment, although more show clinically sig
-
nificant reductions in marijuana use and associated
problems.
30-33
In comparison, a recent study of an effec-
tive treatment for cocaine dependence (community re
-
inforcement therapy plus contingency management)
reported similar abstinence rates.
35
Approximately
40% of the cocaine patients who received this inter-
vention, as well as 20% of those receiving community
reinforcement therapy without contingent reinforce-
ment, were abstinent at the end of treatment. Similarly,
in a large multisite study on treatments for alcohol de-
pendence (Project Match), approximately 20% to 25%
of outpatients who received behavioral coping-skills
therapy or motivational enhancement therapy were ab-
stinent at the end of treatment.
37
Rates of relapse among
cannabis-dependent patients also appear similar to
other substances. A substantial proportion (approxi-
mately 30%) of individuals who achieve 2 or more
weeks of abstinence relapse to pretreatment levels of
use during the 6 months following treatment.
38
Of course, cross-study comparisons of treatment
outcome pose many methodological problems; none
-
theless, the cursory comparison provided here suggests
that the treatment response of cannabis-dependent out
-
patients is similar to that observed with other sub
-
stances of abuse. Clearly, like other substance depend
-
encies, cannabis dependence is not easily treated, and
there appears to be ample room for enhancement of
outcomes.
SUMMARY AND
FUTURE DIRECTIONS
Recent advances indicate that dependence develops
to cannabis in much the same way as with other drugs.
As with other abused substances, many individuals
use cannabis without significant consequence, but oth
-
ers misuse, abuse, or become dependent and
experience adverse outcomes. Substantial impairment
in psychosocial functioning occurs with cannabis de
-
pendence, although in general such effects appear less
severe than those associated with alcohol, heroin, or
cocaine dependence. Nonetheless, substantial num
-
bers of individuals seek treatment for cannabis de
-
pendence, and the effectiveness of such treatments ap
-
pears similar in magnitude to that observed with
treatments for other drug dependencies.
Future clinical research efforts might focus on the
development of more potent psychosocial interven
-
tions, testing of pharmacotherapies, and combined ap
-
proaches. For example, marijuana abusers may benefit
from treatment approaches that seek to reduce drug use
by systematically applying natural or contrived conse
-
quences (i.e., contingency management) to enhance
and sustain efforts to quit using.
31
Such approaches
may be particularly beneficial in this population be-
cause their motivation to change appears to be lower
and more variable than other types of drug abusers, per-
haps because the acute consequences of cannabis de-
pendence are not as severe. Combining effective
psychosocial treatments offers another method that
may enhance treatment effectiveness. Behavior ther-
apy, motivational enhancement therapy, and contin-
gency management can be easily integrated and tested
in controlled trials; indeed, initial evaluations of such
efforts have shown promise.
31,39
Although youth younger than age 20 account for al-
most half the treatment admissions for marijuana de-
pendence, no randomized controlled trials specifically
for adolescent marijuana dependence have been pub
-
lished. A recent multisite study has been completed,
and preliminary findings are consistent with those re
-
ported with adults.
40
Behaviorally based treatments ap
-
pear effective, but the magnitude of treatment response
leaves much room for improvement. Additional con
-
trolled trials are needed in this area. Moreover , crimi
-
nal justice system involvement prompts a substantial
proportion of treatment admissions for cannabis de
-
pendence, particularly in young adults and adoles
-
cents, yet clinical approaches that systematically inte
-
grate the judicial system into the treatment process
have yet to be tested.
Pharmacotherapies for cannabis dependence have
not been evaluated. Now that the validity and severity
of cannabis dependence disorder have been estab
-
lished, a neurobiological cannabinoid system has been
identified, and the treatment response achieved with
effective psychosocial therapies has identified many
nonresponders, the exploration of potential medica
-
NOVEMBER SUPPLEMENT 31
S
DEVELOPMENT AND CONSEQUENCES OF CANNABIS DEPENDENCE
Page 4
tions for cannabis dependence is warranted. The iden
-
tification of the cannabinoid receptor (CB1), which has
a central role in mediating the psychoactive effects of
marijuana, creates new opportunities for the develop
-
ment of agonist or antagonist therapies. The use of
medications to alleviate withdrawal symptoms will
likely prove useful in treatment efforts. Moreover , as
with nicotine and alcohol dependence, the identifica
-
tion of compounds that affect mood or craving may also
show efficacy for treating cannabis dependence.
Last, many marijuana abusers may avoid seeking
treatment because of ambivalence about the seriousness
of their problem. Efforts directed at this non-treatment-
seeking population could create opportunities to pro
-
vide services that reduce problematic marijuana use.
One such intervention, the Marijuana Check-Up, is cur
-
rently under investigation and has shown promise.
41
REFERENCES
1. Griffiths RR, Bigelow GE, Henningfield JE: Similarities in animal
and human drug-taking behavior, in: Mello NK (ed.), Advances in
Substance Abuse: Behavioral and Biological Research. Greenwich,
CT: JAI, 1980;1-90.
2. Tanda G, Munzar P, Goldberg S: Self-administration behavior is
maintained by the psychoactive ingredient of marijuana in squirrel
monkeys. Neuroscience 2000;3(11):1073-1074.
3. Compton DR, Dewey WL, Martin BR: Cannabis dependence and
tolerance production. Advances in Alcohol & Substance Abuse 1990;
9:129-147.
4. Stephens RS, Roffman RA: Adult marijuana dependence, in: Baer
JS, Marlatt GA, McMahon RJ (eds.), Addictive Behaviors across the
Lifespan: Prevention, Treatment, and Policy Issues. Thousand Oaks,
CA: Sage, 1994;243-273.
5. American Psychiatric Association: Diagnostic and Statistical
Manual of Mental Disorders. 4th ed. Washington, DC: American Psy
-
chiatric Association, 1994.
6. World Health Organization: ICD-10 Classification of Mental and
Behavioural Disorders: Clinical Descriptions and Diagnostic Guide
-
lines. Geneva, Switzerland: World Health Organization, 1992.
7. Anthony JC, Helzer JE: Syndromes of drug abuse and dependence,
in: Robins LN, Regier DA (eds.), Psychiatric Disorders in America.
New York: Free Press, 1991;116-154.
8. Anthony JC, Warner LA, Kessler RC: Comparative epidemiology of
dependence on tobacco, alcohol, controlled substances and inhal
-
ants: basic findings from the National Comorbidity Survey . Experi
-
mental and Clinical Psychopharmacology 1994;2:244-268.
9. Hall W, Solowij N, Lemon, J: The Health and Psychological Conse
-
quences of Cannabis Use. National Drug Strategy Monograph No. 25.
Canberra: Australian Government Publication Services, 1994.
10. Kandel DB, Davis M: Progression to regular marijuana involve
-
ment: phenomenology and risk factors of near daily use, in: Glantz M,
Pickens R (eds.), Vulnerability to Drug Abuse. W ashington, DC:
American Psychological Association, 1992;221-253.
11. Stephens RS, Roffman RA, Simpson EE: Adult marijuana users
seeking treatment. Journal of Consulting & Clinical Psychology
1993;61:1100-1104.
12. Budney AJ, Radonovich KJ, Higgins ST, W ong CJ: Adults seeking
treatment for marijuana dependence: a comparison to cocaine-
dependent treatment seekers. Experimental and Clinical Psycho-
pharmacology 1998;6(4):419-426.
13. Copeland J, Swift W, Rees V: Clinical profile of participants in a
brief intervention program for cannabis use disorder. Journal of Sub
-
stance Abuse Treatment 2001;20:45-52.
14. SAMHSA: National Admissions to Substance Abuse Treatment
Services: The Treatment Episode Data Set (TEDS) 1992-1996.
Rockville, MD: U.S. Department of Health and Human Services,
1998.
15. Torres ML, Mattik RP, Chen R, Baillie A: Clients of Treatment Ser
-
vice Agencies: March 1995 Census Findings
. Canberra, Australia:
Commonwealth Department of Health and Human Services, 1995.
16. Devane W A, Dysarz F A, Johnson MR, Melvin LS, Howlett AC: De
-
termination and characterization of a cannabinoid receptor in rat
brain. Molecular Pharmacology 1988;34:605-613.
17. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B,
Congy C, et al: SR141716A, a potent and selective antagonist of the
brain cannabinoid receptor . FEBS Letters 1994;350:240-244.
18. Aceto M, Scates S, Lowe J, Martin B: Dependence on delta-9
tetrahydrocannabinol: studies on precipitated and abrupt with-
drawal. Journal of Pharmacology and Experimental Therapeutics
1996;278:1290-1295.
19. Lichtman AH, W iley JL, LaVecchia KL, Veviaser ST, Arthur DB,
W ilson DM, et al: Effects of SR 141716A after acute or chronic
cannabinoid administration in dogs. European Journal of Pharma-
cology 1998;357:139-148.
20. Haney M, Comer SD, Ward AS, Foltin RW, Fischman MW : Absti-
nence symptoms following oral THC administration to humans.
Psychopharmacology 1999;14:385-394.
21. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW: Ab-
st inence symptoms following smoked marijuana in humans.
Psychopharmacology 1999;14:395-404.
22. Budney AJ, Hughes JR, Moore BA, Novy PL: Marijuana absti
-
nence effects in marijuana smokers maintained in their home envi
-
ronment. Archives of General Psychiatry 2001;58:917-924.
23. Kouri EM, Pope HG: Abstinence symptoms during withdrawal
from chronic marijuana use. Experimental and Clinical Psychopharma-
cology 2000;8(4):483-492.
24. Budney AJ, Moore BA, Vandrey R, Hughes JR: The Timecourse
and Severity of Cannabis W ithdrawal (under review). University of
Vermont.
25. Budney AJ, Novy P, Hughes JR: Marijuana withdrawal among
adults seeking treatment for marijuana dependence. Addiction 1999;
94(9):1311-1321.
26. Crowley TJ, Macdonald MJ, Whitmore EA, Mikulich SK: Canna
-
bis dependence, withdrawal, and reinforcing effects among adoles
-
cents with conduct symptoms and substance use disorders. Drug and
Alcohol Dependence 1998;50:27-37.
27. Hughes JR, Higgins ST, Bickel WK: Nicotine withdrawal versus
other drug withdrawal syndromes: similarities and dissimilarities.
Addiction 1994;89:1461-1470.
28. deFonseca FR, Carrera MRA, Navarro M, Koob GF, W eiss F: Acti
-
vation of corticotropin-releasing factor in the limbic system during
cannabinoid withdrawal. Science 1997;276:2050-2054.
32S J Clin Pharmacol 2002;42:28S-33S
BUDNEY AND MOORE
Page 5
29. Diana M, Melis M, Muntoni AL, Gessa GL: Mesolimbic
dopaminergic decline after cannabinoid withdrawal. Proceedings of
the National Academy of Sciences, USA 1998;95:10269-10273.
30. Stephens RS, Roffman RA, Simpson EE: Treating adult marijuana
dependence: a test of the relapse prevention model. Journal of Con
-
sulting and Clinical Psychology 1994;62:92-99.
31. Budney AJ, Higgins ST, Radonovich KJ, Novy PL: Adding
voucher -based incentives to coping-skills and motivational enhance
-
ment improves outcomes during treatment for marijuana depend
-
ence. Journal of Consulting and Clinical Psychology 2000;68:
1051-1061.
32. Copeland J, Swift W, Roffman R, Stephens R: A randomized con
-
trolled trial of brief cognitive-behavioral interventions for cannabis
use disorder . Journal of Substance Abuse Treatment 2001;21:55-64.
33. Stephens RS, Roffman RA, Curtin L: Comparison of extended ver
-
sus brief treatments for marijuana use. Journal of Consulting and
Clinical Psychology 2000;68:898-908.
34. Bickel WK, Amass L, Higgins ST, Badger GJ, Esch RA: Effects of
adding a behavioral treatment to opioid detoxification with
buprenorphine. Journal of Consulting and Clinical Psychology 1997;
65:803-810.
35. Higgins ST, W ong CJ, Badger GJ, Ogden DH, Dantona R: Contin
-
gent reinforcement increases cocaine abstinence during outpatient
treatment and 1 year of follow up. Journal of Consulting and Clinical
Psychology 2000;68:64-72.
36. Project Match Research Group: Matching alcoholism treatments
to client heterogeneity: Project MATCH posttreatment drinking out
-
comes. Journal of Studies on Alcohol 1997;22:7-29.
37. Project Match Research Group: Matching alcoholism treatments
to client heterogeneity: treatment main effects and matching effects
on drinking during treatment. Journal of Studies on Alcohol 1998;
59:631-639.
38. Moore BA, Budney AJ: Relapse in Outpatient Treatment for Mari
-
juana Dependence (under review). University of Vermont.
39. Higgins ST, Budney AJ, Bickel WK, Foerg F, Donham R, Badger G:
Incentives improve outcome in outpatient behavioral treatment of
cocaine dependence. Archives of General Psychiatry 1994;54:
568-576.
40. Dennis ML, Babor TF, Diamond G, Donalson J, Godley SH, Tims F,
et al: The Cannabis Youth Treatment (CYT) Experiment: Preliminary
Findings [Online]. Retrieved from www.chestnut.org/LI/cyt/findings/
index.html
41. Stephens RS, Roffman RA, Williams CD, Adams S, Burke R,
Campbell A: The marijuana check-up outcomes. Paper presented at
the annual convention of the American Psychological Association,
Chicago, August 2002.
NOVEMBER SUPPLEMENT 33
S
DEVELOPMENT AND CONSEQUENCES OF CANNABIS DEPENDENCE
Page 6
  • Source
    • "van der Pol). to target the prevention and treatment specifically at frequent users at a high risk of dependence. The distinction between non-dependent and dependent frequent use is important, because dependent users, by definition , experience significant psychosocial impairments related to reduced control over their cannabis use, whereas other frequent users do not develop such drug-related problems (Budney and Moore, 2002; Looby and Earleywine, 2007; Temple et al., 2011). This distinction is especially important since cannabis use per se is regarded to be relatively harmless (Nutt et al., 2010; Van Amsterdam et al., 2010). "
    [Show abstract] [Hide abstract] ABSTRACT: Aims: To examine the course and the predictors of the persistence of cannabis dependence. Methods: Through cannabis outlets and chain referral, a prospective enriched community cohort of 207 young adults (aged 18-30) with DSM-IV cannabis dependence at baseline (T0) was formed and followed-up after 1.5 (T1) and 3 (T2) years. The presence of cannabis dependence, cannabis-related problems, functional impairment and treatment was assessed using the Composite International Diagnostic Interview (CIDI 3.0) and the Sheehan Disability Scale (SDS). Predictors of persistence were lifetime cannabis abuse and dependence symptoms, cannabis use characteristics, distant vulnerability factors (e.g. childhood adversity, family history of psychological/substance use problems, impulsivity, mental disorders), and proximal stress factors (recent life events, social support). Results: Four groups were distinguished: persistent dependent (DDD: 28.0%), stable non-persistent (DNN: 40.6%), late non-persistent (DDN: 17.9%) and recurrent dependent (DND: 13.5%). At T2, persisters (DDD) reported significantly more (heavy) cannabis use and cannabis problems than non-persisters (DNN/DDN/DND). Treatment seeking for cannabis-related problems was rare, even among persisters (15.5%). The number (OR = 1.23 (1.03-1.48)) and type ('role impairment' OR = 2.85 (1.11-7.31), 'use despite problems' OR = 2.34 (1.15-4.76)) of lifetime cannabis abuse/dependence symptoms were the only independent predictors of persistence with a total explained variance of 8.8%. Conclusions: Persistence of cannabis dependence in the community is low, difficult to predict, and associated with a negative outcome. The substantial proportion of stable non-persisters suggests that screening and monitoring or low-threshold brief interventions may suffice for many non-treatment-seeking cannabis-dependent people. However, those with many lifetime abuse/dependence symptoms may benefit from more intensive interventions. © 2015 S. Karger AG, Basel.
    Full-text · Article · May 2015 · European Addiction Research
  • Source
    • "van der Pol). to target the prevention and treatment specifically at frequent users at a high risk of dependence. The distinction between non-dependent and dependent frequent use is important, because dependent users, by definition , experience significant psychosocial impairments related to reduced control over their cannabis use, whereas other frequent users do not develop such drug-related problems (Budney and Moore, 2002; Looby and Earleywine, 2007; Temple et al., 2011). This distinction is especially important since cannabis use per se is regarded to be relatively harmless (Nutt et al., 2010; Van Amsterdam et al., 2010). "
    [Show abstract] [Hide abstract] ABSTRACT: Frequent cannabis users are at high risk of dependence, still most (near) daily users are not dependent. It is unknown why some frequent users develop dependence, whereas others do not. This study aims to identify predictors of first-incidence DSM-IV cannabis dependence in frequent cannabis users. A prospective cohort of frequent cannabis users (aged 18-30, n=600) with baseline and two follow-up assessments (18 and 36 months) was used. Only participants without lifetime diagnosis of DSM-IV cannabis dependence at baseline (n=269) were selected. Incidence of DSM-IV cannabis dependence was established using the Composite International Diagnostic Interview version 3.0. Variables assessed as potential predictors of the development of cannabis dependence included sociodemographic factors, cannabis use variables (e.g., motives, consumption habits, cannabis exposure), vulnerability factors (e.g., childhood adversity, family history of mental disorders or substance use problems, personality, mental disorders), and stress factors (e.g., life events, social support). Three-year cumulative incidence of cannabis dependence was 37.2% (95% CI=30.7-43.8%). Independent predictors of the first incidence of cannabis dependence included: living alone, coping motives for cannabis use, number and type of recent negative life events (major financial problems), and number and type of cannabis use disorder symptoms (impaired control over use). Cannabis exposure variables and stable vulnerability factors did not independently predict first incidence of cannabis dependence. In a high risk population of young adult frequent cannabis users, current problems are more important predictors of first incidence cannabis dependence than the level and type of cannabis exposure and stable vulnerability factors.
    Full-text · Article · Jul 2013 · Drug and alcohol dependence
  • Source
    • "Cannabis dependence is associated with a drug withdrawal syndrome that appears comparable to that observed with tobacco withdrawal (Vandrey et al., 2008; Vandrey et al., 2005b), and dependent users often fail at attempts to quit or reduce use (Budney and Moore, 2002). The cannabis withdrawal syndrome has been characterized in a number of controlled laboratory and clinical survey studies (Budney et al., 2004; Haney, 2005). "
    [Show abstract] [Hide abstract] ABSTRACT: Sleep difficulty is a common symptom of cannabis withdrawal, but little research has objectively measured sleep or explored the effects of hypnotic medication on sleep during cannabis withdrawal. Twenty daily cannabis users completed a within-subject crossover study. Participants alternated between periods of ad libitum cannabis use and short-term cannabis abstinence (3 days). Placebo was administered at bedtime during one abstinence period (withdrawal test) and extended-release zolpidem, a non-benzodiazepine GABA(A) receptor agonist, was administered during the other. Polysomnographic (PSG) sleep architecture measures, subjective ratings, and cognitive performance effects were assessed each day. During the placebo-abstinence period, participants had decreased sleep efficiency, total sleep time, percent time spent in Stage 1 and Stage 2 sleep, REM latency and subjective sleep quality, as well as increased sleep latency and time spent in REM sleep compared with when they were using cannabis. Zolpidem attenuated the effects of abstinence on sleep architecture and normalized sleep efficiency scores, but had no effect on sleep latency. Zolpidem was not associated with any significant side effects or next-day cognitive performance impairments. These data extend prior research that indicates abrupt abstinence from cannabis can lead to clinically significant sleep disruption in daily users. The findings also indicate that sleep disruption associated with cannabis withdrawal can be attenuated by zolpidem, suggesting that hypnotic medications might be useful adjunct pharmacotherapies in the treatment of cannabis use disorders.
    Full-text · Article · Feb 2011 · Drug and alcohol dependence
Show more